new drug discovery projects
unique chemical compounds in the ELF library
About the European Lead Factory
Within the framework of the European Lead Factory, a Joint European Compound Library (JECL) has been created from two unique sources. First, over 300,000 compounds have been selected from previously inaccessible private company (EFPIA) collections. Second, a further 200,000 innovative compounds have been synthesized from crowd sourcing ideas by European Lead Factory chemistry partners. The initiative also offers ultra-high throughput (uHTS) screening of novel drug targets against the JECL at the European Screening Centre (ESC).
The new ESCulab project (European Screening Centre; Unique Library for Attractive Biology), supported by the Innovative Medicines Initiative (IMI), will use the well-established European Lead Factory brand in order to continue its success story of speeding up drug discovery.
Visit the European Lead Factory website for more information.
Sustaining consortium success as a trusted partner
The project reaches out to academics and SMEs throughout Europe. Lygature helped to drive development from the beginning, establishing and managing an international consortium of 20 (previously 30) partners. From January 2016, a broad range of resources and support are provided under the Lygature brand, including:
- Scientific management and leadership. Lygature is responsible for scientific management at the Program Office, where drug discovery proposals are being recruited and where the review and selection processes are coordinated. In addition, Lygature supports the Ethics Advisory Board and is coordinator of the IMI ESCulab grant;
- Trusted partner. As an independent enabler with no conflicting interests, Lygature guides public and private drug discovery;
- Sustainability. Lygature coordinates sustainability discussions and planning for the European Screening Centre and the collaborative drug discovery concept;
- Communications. Other contributions include brand building of EU Lead Factory; communicating and disseminating (scientific) articles, policies and guidelines; and use of our intranet platform for secured document sharing.
The European Lead Factory is an important example of the Lygature mission to bring academia, industry and society together in collaborative projects that allow participants to benefit from shared resources. It has required extensive expertise in both management and science, and has helped to build many long-term partnerships which Lygature continues to support.
Top image: Screening Robot at the European Screening Centre (courtesy of the Pivot Park Screening Centre)
Lygature together with
The European Lead Factory, Europe’s largest collaborative drug discovery platform, continues its success story
The European Lead Factory secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in the new project ESCulab (European Screening Centre: unique library for attractive biology) under the European Lead Factory brand.
Over the next five years, the European Lead Factory will initiate 185 new drug discovery projects by screening medically relevant drug targets from European researchers, small and medium-sized enterprises and pharmaceutical industry against the ELF library of 550,000 unique chemical compounds.
The successful concept of the European Lead Factory has already encouraged additional private partners to join. The ESCulab Project welcomes the two pharmaceutical companies Servier and Grünenthal as well as the Medicines for Malaria Venture (MMV), the leading product development partnership in the field of antimalarial drug research and development.
Lygature, involved as of from the early start of the European Lead Factory is proud to see that the concept of collaborative drug discovery has been so successful that it can continue its work. Project Coordinator Jon de Vlieger: “the European Lead Factory six years ago with the idea to combine the best of academia with the best of industry. We have proven that this is a very successful model for early drug discovery. With new partners and new funding we can continue to find leads for novel drugs based on new biological insights. Part of our mission now is to establish a sustainable business model for the European Lead Factory.”
Read the full press release here.
Seeding tomorrow’s priority medicines
The European Lead Factory has successfully accelerated the process of drug discovery. A recently published public summary of results so far clearly shows the benefits of collaborative drug discovery in the European arena.
The European Lead Factory contributing to the fight against Alzheimers
The key goal of ELF is to create validated hit series. Another successful ELF programme aimed at identifying small molecules for the treatment of Alzheimer’s Disease has culminated in the most potent compound yet identified by the ELF team at Newhouse, Scotland with the most active compound reaching 100pM. These compounds also have excellent physicochemical properties. Read more